Andrew K. Joe

20.0k total citations · 3 hit papers
53 papers, 3.5k citations indexed

About

Andrew K. Joe is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew K. Joe has authored 53 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 20 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew K. Joe's work include Melanoma and MAPK Pathways (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Andrew K. Joe is often cited by papers focused on Melanoma and MAPK Pathways (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Andrew K. Joe collaborates with scholars based in United States, France and Japan. Andrew K. Joe's co-authors include I. Bernard Weinstein, Masumi Suzui, Danhua Xiao, Hui Liu, I B Weinstein, Răzvan Cristescu, Patrick A. Ott, Jared Lunceford, Mark Ayers and Sarina A. Piha‐Paul and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Virology.

In The Last Decade

Andrew K. Joe

52 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

2018 656 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
Oncogene Addiction

2008 615 citations I. Bernard Weinstein, Andrew K. Joe profile →
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

2006 511 citations I. Bernard Weinstein, Andrew K. Joe profile →

Peers

Countries citing papers authored by Andrew K. Joe

Since Specialization

Citations

This map shows the geographic impact of Andrew K. Joe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew K. Joe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew K. Joe more than expected).

Fields of papers citing papers by Andrew K. Joe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew K. Joe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew K. Joe. The network helps show where Andrew K. Joe may publish in the future.

Co-authorship network of co-authors of Andrew K. Joe

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew K. Joe. A scholar is included among the top collaborators of Andrew K. Joe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew K. Joe. Andrew K. Joe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial 2024 ·Annals of Oncology ·C. Le Tourneau, (unknown), C. Even, Assuntina G. Sacco, Amaury Daste, Irene Braña, C. van Herpen, Thibault Mazard, (unknown), (unknown), Andrew K. Joe, (unknown), (unknown), (unknown), Lokesh Jain, (unknown), Richard de Leeuw, Antoine Hollebecque	2
2	Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14). 2024 ·Journal of Clinical Oncology ·Mariana Brandão, Jon Zugazagoitia, Anne‐Marie C. Dingemans, M. Duruisseaux, (unknown), Óscar Juan, Alexander I. Spira, Cécile Vicier, Gérard Zalcman, (unknown), (unknown), Petra Doze, Andrew K. Joe, Gianluca Laus, Enriqueta Felip	3
3	Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab. 2024 ·Journal of Clinical Oncology ·Chrisann Kyi, (unknown), Sylvie Rottey, Ignacio Melero, Diana Mittag, (unknown), Kees Bol, (unknown), Andrew K. Joe, Gianluca Laus, Víctor Moreno	4
4	Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study. 2024 ·Journal of Clinical Oncology ·Jérôme Fayette, Florian Clatot, Irene Braña, Esma Saâda, (unknown), Thibault Mazard, Cesar A. Perez, Josep Tabernero, Christophe Le Tourneau, Antoine Hollebecque, (unknown), Elisa Fontana, Shumei Kato, Assuntina G. Sacco, (unknown), Jan Paul de Boer, Jessica A. Hellyer, (unknown), Andrew K. Joe, Amaury Daste	12
5	The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions 2024 ·Future Oncology ·Dong‐Wan Kim, Alison M. Schram, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, M. Duruisseaux, Stephen V. Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M. Cleary, Christoph Springfeld, Cindy Neuzillet, Andrew K. Joe, (unknown), (unknown), Kōichi Goto	27
6	1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Alison M. Schram, Kōichi Goto, Dongwook Kim, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, (unknown), Joon Oh Park, Natasha B. Leighl, Teresa Macarulla, Stephen V. Liu, Mohammed Najeeb Al Hallak, James M. Cleary, Cindy Neuzillet, Yasushi Goto, Andrew K. Joe, (unknown), (unknown), Alexander Drilon	10
7	362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC) 2023 ·Annals of Oncology ·Paolo Bossi, (unknown), Irene Braña, Víctor Moreno, Valentina Boni, Philippe Jamme, Justin Call, Chunhong Yan, (unknown), (unknown), Andrew K. Joe, (unknown), Amaury Daste	5
8	595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Dongwook Kim, Kōichi Goto, Alison M. Schram, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, (unknown), Joon Oh Park, Natasha B. Leighl, T. Macarulla Mercadé, Stephen V. Liu, Mohammed Najeeb Al Hallak, James M. Cleary, Cindy Neuzillet, Yasushi Goto, Andrew K. Joe, (unknown), (unknown), Alexander Drilon	1
9	1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC) 2023 ·Annals of Oncology ·Alison M. Schram, Teresa Macarulla, James M. Cleary, Cindy Neuzillet, Dirk Arnold, Kim A. Reiss, Tanios Bekaii‐Saab, Jordi Rodón, Kōichi Goto, Sun Young Rha, M. Duruisseaux, Natasha B. Leighl, Benjamin A. Weinberg, Mohammed Najeeb Al Hallak, Andrew K. Joe, (unknown), Ernesto Wasserman, (unknown), Alexander Drilon, Eileen M. O’Reilly	11
10	T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 breakdown → 2018 ·Journal of Clinical Oncology ·Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul, Albiruni R. Abdul Razak, Jaafar Bennouna, Jean‐Charles Soria, Hope S. Rugo, Roger B. Cohen, Bert H. O’Neil, Janice M. Mehnert, Juanita Lopez, Toshihiko Doi, Emilie M.J. van Brummelen, Răzvan Cristescu, Ping Yang, Kenneth Emancipator, Karen Stein, Mark Ayers, Andrew K. Joe, Jared Lunceford	656
11	Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) 2017 ·Annals of Oncology ·Patrick A. Ott, Y-J. Bang, A.R. Abdul Razak, Jaafar Bennouna, J.C. Soria, Hope S. Rugo, Roger B. Cohen, Bert H. O’Neil, Janice M. Mehnert, Juanita Lopez, Toshihiko Doi, Emilie M.J. van Brummelen, Diane Levitan, Guisheng Zhao, Kenneth Emancipator, Karen Stein, Andrew K. Joe, Mark Ayers, Jared Lunceford, Sarina A. Piha‐Paul	5
12	Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers 2017 ·Annals of Oncology ·Luis A. Díaz, Aurélien Marabelle, T.W. Kim, Ravit Geva, Eric Van Cutsem, Thierry André, Paolo A. Ascierto, Michele Maio, J.P. Delord, Maya Gottfried, Rosine Guimbaud, D. Jaeger, Elena Élez, Takayuki Yoshino, Andrew K. Joe, (unknown), (unknown), Scott K. Pruitt, Soonmo Peter Kang, D. Le	52
13	Somatic evolution of head and neck cancer — Biological robustness and latent vulnerability 2012 ·Molecular Oncology ·Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Masumi Suzui, Andrew K. Joe	15
14	A case of laryngeal carcinoma in a young adult with dyskeratosis congenita 2010 ·International Journal of Clinical Oncology ·Noritaka Komune, Takashi Hara, Akihiro Tamae, Kunio Izu, Y. Tokura, Andrew K. Joe, Muneyuki Masuda	5
15	Fear and loathing in the Caribbean: three studies of fear and cancer screening in Brooklyn's immigrant Caribbean subpopulations 2009 ·Infectious Agents and Cancer ·Nathan S. Consedine, (unknown), David Horton, Andrew K. Joe, Luisa N. Borrell, Paul Ramírez, (unknown), James M. McKiernan, Judith S. Jacobson, Carol Magai, Alfred I. Neugut	14
16	(-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells 2008 ·Carcinogenesis ·Seiji Adachi, Tomokazu Nagao, (unknown), Andrew K. Joe, Masahito Shimizu, Rie Matsushima‐Nishiwaki, Osamu Kozawa, Hisataka Moriwaki, Frederick R. Maxfield, I. Bernard Weinstein	78
17	A case of primary Hodgkin's lymphoma of the parotid gland 2008 ·Auris Nasus Larynx ·Muneyuki Masuda, (unknown), Andrew K. Joe, Naoya Hirakawa, Shizuo Komune	7
18	Prevention of Bone Loss After Withdrawal of Tamoxifen 2008 ·Endocrine Practice ·Adi Cohen, Jessica Fleischer, (unknown), (unknown), Andrew K. Joe, Dawn L. Hershman, Donald J. McMahon, Shonni J. Silverberg	14
19	Supplementing previously treated anestrous dairy cows with progesterone does not increase first-service conception rate 2004 ·Theriogenology ·D.W. Hanlon, (unknown), (unknown), Andrew K. Joe	9
20	Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells 2003 ·PubMed ·Andrew K. Joe, Hui Liu, Danhua Xiao, Jae‐Won Soh, John T. Pinto, David G. Beer, Gary A. Piazza, William J. Thompson, I. Bernard Weinstein	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact